Dulaglutide
Dulaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist used to improve blood glucose control in people with type 2 diabetes mellitus. It is a recombinant fusion protein that shares structural characteristics with human GLP-1 and is modified to resist rapid enzymatic breakdown, allowing it to remain active in the body for an extended period. Dulaglutide works by stimulating glucose-dependent insulin secretion from pancreatic beta cells, suppressing inappropriate glucagon release, and slowing gastric emptying. These actions help reduce blood glucose levels, particularly after meals, while its glucose-dependent mechanism is associated with a relatively low risk of hypoglycaemia when used alone. It may also reduce appetite and support modest weight reduction in some patients. Dulaglutide is administered as a subcutaneous injection once weekly using a prefilled injection device. It can be prescribed alone when other glucose-lowering medicines are unsuitable or alongside treatments such as metformin, SGLT2 inhibitors, and insulin. Clinical studies have also demonstrated cardiovascular benefits in certain adults with type 2 diabetes, making it an important therapeutic option for patients requiring both glycaemic management and cardiovascular risk reduction.
Linked Products
4
FAQs
7
References
2
Overview
Dulaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist used to improve blood glucose control in people with type 2 diabetes mellitus. It is a recombinant fusion protein that shares structural characteristics with human GLP-1 and is modified to resist rapid enzymatic breakdown, allowing it to remain active in the body for an extended period. Dulaglutide works by stimulating glucose-dependent insulin secretion from pancreatic beta cells, suppressing inappropriate glucagon release, and slowing gastric emptying. These actions help reduce blood glucose levels, particularly after meals, while its glucose-dependent mechanism is associated with a relatively low risk of hypoglycaemia when used alone. It may also reduce appetite and support modest weight reduction in some patients. Dulaglutide is administered as a subcutaneous injection once weekly using a prefilled injection device. It can be prescribed alone when other glucose-lowering medicines are unsuitable or alongside treatments such as metformin, SGLT2 inhibitors, and insulin. Clinical studies have also demonstrated cardiovascular benefits in certain adults with type 2 diabetes, making it an important therapeutic option for patients requiring both glycaemic management and cardiovascular risk reduction.
Background and Date of Approval
Dulaglutide was developed by Eli Lilly and Company as a long-acting GLP-1 receptor agonist for the management of type 2 diabetes mellitus. Its molecular structure consists of two modified GLP-1 analogue sequences linked to a modified human immunoglobulin G4 (IgG4) Fc fragment, which prolongs its circulating half-life and supports once-weekly administration. The molecule was evaluated through the AWARD clinical trial programme, which assessed its effectiveness and safety as monotherapy and in combination with other glucose-lowering treatments. Its cardiovascular safety and outcomes were further evaluated in the REWIND trial, which demonstrated a reduction in major adverse cardiovascular events in adults with type 2 diabetes and cardiovascular risk factors. The US Food and Drug Administration (FDA) initially approved dulaglutide in September 2014, and the European Medicines Agency (EMA) granted marketing authorisation for Trulicity on 21 November 2014. In India, dulaglutide has been included in Central Drugs Standard Control Organisation (CDSCO) regulatory proceedings, including consideration of updated product information and post-marketing clinical data. Regulatory indications and approved strengths may differ between countries.
Uses
Dulaglutide is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. It can be used as monotherapy when metformin is inappropriate because of intolerance or contraindications, or as an add-on treatment alongside other glucose-lowering medicines such as metformin, sulphonylureas, pioglitazone, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and insulin. In the United States and European Union, approved indications also include eligible paediatric patients aged 10 years and above with type 2 diabetes, subject to local prescribing recommendations. In adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors, dulaglutide can reduce the risk of major adverse cardiovascular events, including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke, under the applicable regulatory indication. It is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis.
Administration
Dulaglutide is administered as a subcutaneous injection once weekly using a prefilled, single-dose injection pen. It can be injected into the abdomen, thigh, or upper arm, and administration may take place at any time of the day, with or without food. For adults, the usual starting dose is 0.75 mg once weekly when used as monotherapy or according to the applicable product information. When additional glycaemic control is required, the dose may be increased to 1.5 mg once weekly after at least four weeks. Depending on the approved product strength and local prescribing information, further escalation to 3 mg and then 4.5 mg once weekly may be considered at intervals of at least four weeks. The maximum adult dose in the US and EU prescribing information is 4.5 mg once weekly. For eligible paediatric patients aged 10 years and above, the recommended starting dose is 0.75 mg once weekly, with an increase to 1.5 mg when required; the paediatric maximum is 1.5 mg weekly. If a dose is missed, it can generally be administered when remembered, provided at least 72 hours remain before the next scheduled dose. Treatment duration depends on glycaemic response, tolerability, cardiovascular risk considerations, and the overall diabetes management plan. Blood glucose, HbA1c, renal function when clinically indicated, and gastrointestinal tolerability should be monitored during treatment.
Side Effects
The most frequently reported adverse effects of dulaglutide involve the gastrointestinal system. These include nausea, diarrhoea, vomiting, abdominal discomfort, abdominal pain, reduced appetite, and indigestion. Nausea and vomiting are more likely during treatment initiation or following dose escalation and may gradually improve as the body adjusts to therapy. Some patients may experience constipation, bloating, or fatigue. Reduced appetite and delayed gastric emptying may contribute to weight reduction in certain individuals. Hypoglycaemia is generally less common when dulaglutide is used alone but becomes more likely when it is combined with insulin or sulphonylureas. Most gastrointestinal symptoms are mild to moderate and can often be managed through appropriate dose escalation, dietary adjustments, and medical supervision. Persistent or severe symptoms require clinical assessment.
Warnings
Important serious risks associated with dulaglutide include acute pancreatitis, severe gastrointestinal reactions, hypersensitivity reactions, acute kidney injury secondary to dehydration, gallbladder disease, and complications associated with diabetic retinopathy. Dulaglutide carries a boxed warning in the United States regarding thyroid C-cell tumours observed in animal studies. Although the relevance of these findings to humans has not been established, it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Treatment should be discontinued promptly if pancreatitis is suspected and should not be restarted if pancreatitis is confirmed. Severe abdominal pain, persistent vomiting, allergic reactions, or symptoms of gallbladder disease require immediate medical evaluation. Severe hypoglycaemia may occur when dulaglutide is combined with insulin or insulin secretagogues. Patients with significant gastrointestinal disease, particularly severe gastroparesis, require careful assessment because dulaglutide is not recommended in this population. Healthcare professionals should also consider the potential risk of pulmonary aspiration during general anaesthesia or deep sedation in patients receiving GLP-1 receptor agonists.
Precautions
Dulaglutide should be prescribed cautiously in patients with a history of pancreatitis, diabetic retinopathy, gallbladder disease, renal impairment, or significant gastrointestinal disorders. Patients experiencing persistent nausea, vomiting, or diarrhoea should be assessed for dehydration and possible deterioration in renal function. The medicine is not recommended during pregnancy unless the potential benefit justifies the potential risk, and treatment plans should be reviewed when pregnancy is planned or identified. Its use during breastfeeding should be evaluated according to individual clinical circumstances and local prescribing guidance. Dulaglutide delays gastric emptying, which may affect the absorption rate of certain orally administered medicines. Particular attention should be given to oral medicines requiring rapid absorption or close therapeutic monitoring. Concurrent administration with insulin or sulphonylureas may increase hypoglycaemia risk, and adjustment of their doses may be necessary. Combining dulaglutide with another GLP-1 receptor agonist is generally not recommended. Patients should inform healthcare professionals about planned surgical procedures or anaesthesia because delayed gastric emptying may increase aspiration-related concerns. Classic cytochrome P450-mediated drug interactions are uncommon because dulaglutide is a peptide-based biologic molecule.
Expert Tips
Before initiating dulaglutide, healthcare professionals should review the patient's diabetes history, HbA1c, current glucose-lowering medicines, cardiovascular risk profile, gastrointestinal history, and relevant contraindications. Patients should be counselled about the once-weekly injection schedule, correct use of the prefilled pen, appropriate injection sites, and proper storage according to the manufacturer's instructions. Dose escalation should follow the approved prescribing information to improve tolerability and minimise gastrointestinal adverse effects. When dulaglutide is prescribed with insulin or sulphonylureas, clinicians should assess the need for dose reduction to prevent hypoglycaemia. Patients should be advised to maintain adequate fluid intake, particularly if vomiting or diarrhoea occurs. Regular monitoring of HbA1c, blood glucose, body weight, renal function when clinically indicated, and symptoms suggestive of pancreatitis or gallbladder disease is recommended. Patients with existing diabetic retinopathy may require appropriate ophthalmological follow-up. Pharmacists should verify product strength, injection-device instructions, storage conditions, and missed-dose guidance before dispensing. Coordination between diabetologists, primary care physicians, pharmacists, and other healthcare professionals helps support safe and effective long-term treatment.
FAQs
What is Dulaglutide?
Dulaglutide is a long-acting GLP-1 receptor agonist used to improve blood glucose control in patients with type 2 diabetes mellitus. It stimulates glucose-dependent insulin secretion and helps regulate blood glucose levels.
How is Dulaglutide administered?
Dulaglutide is administered as a subcutaneous injection once weekly using a prefilled injection pen. It can be injected into the abdomen, thigh, or upper arm.
What conditions is Dulaglutide used for?
Dulaglutide is primarily used to manage type 2 diabetes mellitus in combination with diet and exercise. It also reduces major cardiovascular event risk in eligible adults with type 2 diabetes under approved indications.
What are common side effects?
Common side effects include nausea, diarrhoea, vomiting, abdominal pain, indigestion, and reduced appetite. These symptoms are often more noticeable when treatment is initiated or the dose is increased.
What serious risks should be monitored?
Important risks include pancreatitis, severe gastrointestinal reactions, thyroid C-cell tumour concerns, gallbladder disease, kidney injury due to dehydration, and serious allergic reactions. Hypoglycaemia should also be monitored when dulaglutide is combined with insulin or sulphonylureas.
How long is treatment continued?
Treatment duration depends on glycaemic response, tolerability, cardiovascular risk, and individual treatment goals. Dulaglutide may be continued long term under regular medical supervision when clinically appropriate.
What monitoring is required during treatment?
Monitoring generally includes HbA1c, blood glucose, gastrointestinal tolerability, body weight, and renal function when indicated. Healthcare professionals should also assess symptoms of pancreatitis, gallbladder disease, hypoglycaemia, and diabetic retinopathy complications.
References
More Molecule Profiles
Browse other published molecule pages in the catalog.
Inactivated Influenza
Inactivated influenza vaccine (IIV) is a preventive vaccine used to protect against seasonal influenza, a contagious respiratory…
View molecule pageDurvalumab
Durvalumab is a human monoclonal antibody belonging to the immune checkpoint inhibitor class of anticancer medicines. It specific…
View molecule pageCYTOKINE REMOVAL
Cytokine removal is an extracorporeal blood-purification approach intended to reduce excessive concentrations of circulating cyto…
View molecule page